Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia ankara-HIV-1 vaccine candidate

by Jeffrey R. Currier, Viseth Ngauy, Mark S. de Souza, Silvia Ratto-Kim, Josephine H. Cox, Victoria R. Polonis, Patricia Earl, Bernard Moss, Sheila Peel, Bonnie Slike, Somchai Sriplienchan, Prasert Thongcharoen, Robert M. Paris, Merlin L. Robb, Jerome Kim, Nelson L. Michael, Mary A. Marovich
Published 2018